MATICAL INNOVATION SL

Their core work

Matical Innovation is a Madrid-based technology SME that develops AI-driven software tools for cancer diagnosis and prognosis, working at the intersection of medical imaging and machine learning. Their core work involves building and deploying radiomics pipelines, predictive models, and imaging biomarker platforms that extract clinically actionable information from MRI and CT scans. In both of their H2020 projects they contributed as a specialist technology partner, bringing software development and AI tooling capability to large clinical-research consortia. Their practical focus spans the full pipeline from raw imaging data to regulatory-compliant, market-ready AI tools for oncology.

What they specialise in

How they've shifted over time

Matical's earliest H2020 work centred on rare and paediatric cancers — neuroblastoma and DIPG — using computational modelling and in-silico simulation to personalise diagnosis. Their second project marks a clear expansion toward common adult cancers (lung, breast, colorectal, prostate) and shifts emphasis from modelling to applied AI tooling, radiomics pipelines, and market-readiness. The trajectory shows a company moving from research-grade simulation toward deployable, regulatory-compliant clinical AI products.

Matical is moving up the technology readiness scale — from computational research on rare cancers toward regulated, market-ready AI products for mainstream oncology indications, making them an increasingly viable partner for MedTech commercialisation projects.

How they like to work

Matical participates exclusively as a consortium partner and has never led a project, suggesting they operate as a specialist technology contributor rather than a project driver. Their two projects both sit within large RIA consortia (PRIMAGE and CHAIMELEON are well-known multi-partner initiatives), indicating comfort working inside complex, multi-national teams. With 28 unique partners across 11 countries from just two projects, their network density is relatively high, pointing to broad exposure rather than a closed circle of repeat collaborators.

Despite only two projects, Matical has built connections with 28 distinct partner organisations spread across 11 countries, which is a strong network density for a two-project SME. Their European reach spans clinical, academic, and industrial partners typical of Horizon health consortia.

What sets them apart

Matical sits in a rare niche: a small private company with direct hands-on experience in two of Europe's most prominent AI-for-oncology H2020 projects, giving them credibility that most SMEs of this size cannot match. Their combination of deep imaging AI expertise and regulatory-pathway awareness (from CHAIMELEON's market-transition focus) makes them valuable to consortia that need both technical execution and a route to clinical deployment. For a consortium builder, they bring SME agility and specialist knowledge without the overhead of a large corporate partner.

Highlights from their portfolio

• PRIMAGE
  The largest of their two projects by EC funding (EUR 380,756) and the one that established their credentials in predictive in-silico cancer modelling, specifically for rare paediatric cancers neuroblastoma and DIPG.
• CHAIMELEON
  A high-profile Horizon project explicitly targeting AI commercialisation in oncology, spanning five cancer types and introducing regulatory compliance as a core objective — directly relevant to MedTech and digital health investors.